No. As of September 2026, MapLight Therapeutics, Inc. (MPLT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 102.4% / 30% · Interest income / Revenue 309400000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 102.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 309400000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 102.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 309400000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.17% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 79.3% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 309400000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 97.1% / 33.33% · (Cash+Recv) / Total Assets 97.1% / 33.33% · Interest income / Revenue 309400000.0% / 5% | Fail |
No. As of September 2026, MapLight Therapeutics, Inc. (MPLT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MapLight Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 309400000.0% of each dividend: MapLight Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.
MapLight Therapeutics, Inc. (NASDAQ: MPLT) is a Healthcare company (Biotechnology) with a market capitalization of $280M. The Maz Rating grades it against the other companies in its sector.
MapLight Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $6.57, MapLight Therapeutics, Inc. trades at 0.8x book value, with an EV/EBITDA of 0.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -61.0%, return on invested capital of -61.7% and a free cash flow yield of -60.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 15.00. Over the past 52 weeks the share price ranged from $6.06 to $40.43, with a beta of 3.01.
MapLight Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 5 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.